For research use only
| Cat No. | ABC-SC0074T |
| Product Type | Human iPSCs |
| Cell Type | Neural Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | iPSC |
| Disease | Normal |
| Storage | Liquid Nitrogen |
HighQC™ Human IPSC-Derived Neural Stem Cell MAPT P301L HET models tauopathy for neurodegeneration research using CRISPR-edited heterozygous P301L mutation.
HighQC™ Human IPSC-Derived Neural Stem Cells-MAPT P301L HET are a human iPSC-derived neural stem cell line with a heterozygous P301L mutation (CCA>CTA) introduced into the MAPT gene using CRISPR-Cas9 gene editing. One allele carries the mutation, and the other remains wild-type. These neural stem cells express typical markers of cortical neural stem and progenitor cells, such as PAX6, FOXG1, and Nestin. These MAPT P301L heterozygous iPSC-Derived NSCs are valuable for investigating targeted interventions at the preclinical stages of tauopathy. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | HighQC™ Human IPSC-Derived Neural Stem Cell MAPT P301L HET, hIPSC-NSC-MAPT-P301L-HET, Human IPSC Neural Stem Cells MAPT P301L Heterozygous |
| Species | Human |
| Cat.No | ABC-SC0074T |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Neural Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | iPSC |
| Disease | Normal |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
This neural stem cell model derived from a heterozygous MAPT P301L iPSC line is used to study tau-driven pathology in a gene-dose-dependent manner. It supports the investigation of altered neuron morphology, tau mislocalization, and neurodegeneration relevant to FTDP-17. Its heterozygous configuration allows for the observation of subtle pathological changes that mirror the early stages of disease progression in human carriers.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Yes. MAPT P301L iPSC-derived neural stem cells can be differentiated into excitatory cortical neurons and are suitable for studies of MAPT-associated neuronal phenotypes and tauopathy in vitro model applications. Following differentiation, the cells express NTRK1, NTRK2 (TrkB), and NTRK3 (TrkC), with functional synaptic activity supported by MEA data. However, tau-related pathological phenotypes have not yet been specifically characterized in this cell line, so validated data on tau pathology or synapse loss are not currently available. A control iPSC-derived neural stem cell line can be provided for comparative studies. This product is available as a custom differentiation project rather than an off-the-shelf product.